Releases
31. August, 2023
August business update
A short update to the great progress we continue to make….thanks for reading!...
Facts
25. August, 2023
New findings supporting CT001
Based on new findings in a 2023 meta-analysis by Fjendbo Galili et al., which...
Releases
24. August, 2023
Second quarter report Q2-2023
US co-development and commercialization partnership signed for CT001 – potential income already from 2024...
Releases
27. June, 2023
Cessatech and Ventis Pharma announce US partnership for CT001
On 27 June – Cessatech A/S (“Cessatech” or “the Company”) announces that the Company...
Releases
12. May, 2023
First quarter report Q1-2023 with Q&A
First quarter report Q1-2023 Study 0205 is progressing, with last patient expected in Q3...
Releases
23. March, 2023
Cessatech announces new Chairman of the Board
On 23 March 2023 Cessatech A/S announces that the Board of Directors has appointed...
Releases
28. February, 2023
Annual Report for the fiscal year 2022
Cessatech today publishes its annual report for the fiscal year 2022, which also includes...
Releases
18. November, 2022
Third quarter report Q3-2022
Cessatech today releases its results for the period 1 July – 30 September 2022....
Releases
14. November, 2022
Successful outcome of Rights issue
The results of the rights issue announced on October 19, 2022 for which the...
Releases
19. October, 2022
DKK 18.3 million capital raise through a 80% guarantee
DKK 18.3 MILLION CAPITAL RAISE THROUGH A 80% GUARANTEED RIGHTS ISSUE TO FINANCE PIVOTAL...
Releases
23. September, 2022
Successful outcome of pharmacokinetic trial in children of lead candidate
Cessatech A/S announces positive topline outcome of its Phase 2 pharmacokinetics trial with CT001...
Releases
5. September, 2022
First patient dosed in pivotal trial of lead product candidate
First patient has been dosed in pivotal trial of lead candidate CT001 The pivotal...